MENU
IDNA
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

IDNA stock forecast, quote, news & analysis

The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
IDNA
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for IDNA with price predictions
Oct 20, 2026

IDNA sees MACD Histogram just turned negative

IDNA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 06, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 51 instances where the indicator turned negative. In 46 of the 51 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for IDNA moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 18 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

IDNA broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 60 cases where IDNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on IDNA as a result. In 75 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.

Following a +5.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDNA advanced for three days, in 238 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

The Aroon Indicator entered an Uptrend today. In 167 of 197 cases where IDNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Merck & Co (NYSE:MRK), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Novavax (NASDAQ:NVAX).

Industry description

The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-. The fund is non-diversified.

Market Cap

The average market capitalization across the iShares Genomics Immunology and Healthcare ETF (IDNA) ETF is 31.54B. The market cap for tickers in the group ranges from 275.53M to 354.36B. MRK holds the highest valuation in this group at 354.36B. The lowest valued company is OCGN at 275.53M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Genomics Immunology and Healthcare ETF (IDNA) ETF was 4%. For the same ETF, the average monthly price growth was 7%, and the average quarterly price growth was 41%. VSTM experienced the highest price growth at 25%, while DNA experienced the biggest fall at -16%.

Volume

The average weekly volume growth across all stocks in the iShares Genomics Immunology and Healthcare ETF (IDNA) ETF was -3%. For the same stocks of the ETF, the average monthly volume growth was -50% and the average quarterly volume growth was -19%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 45
P/E Growth Rating: 55
Price Growth Rating: 48
SMR Rating: 84
Profit Risk Rating: 83
Seasonality Score: 16 (-100 ... +100)
IDNA sees MACD Histogram just turned negative